Experience of olokizumab use in COVID-19 patients

Cover Page

Cite item

Full Text

Abstract

Most subjects with the COVID-19 experience mild to moderate symptoms, but approximately 10% of cases suffer from severe course of disease. IL-6 inhibitors are actively used to neutralize and prevent the «cytokine storm». Olokizumab is a humanized monoclonal antibody belonging to the G4/Kappa immunoglobulin isotype that selectively binds to human IL-6 and effectively neutralizes it.

Aim. To evaluate the efficacy and safety of Artlegia (olokizumab) for the treatment of subjects with a disease caused by the SARS-COV-2 virus in a real-world clinical setting.

Materials and methods. The analysis included data of 610 subjects aged 55.08±12.68 years who received olokizumab at a single dose of 160 mg/mL – 0.4 mL subcutaneously as a preemptive anti-inflammatory therapy. The comparison group included 511 subjects aged 55.23±11.23 years who received standard therapy without IL-6 inhibitors. Control Endpoints: 1. Positive clinical changes on Day 7. 2. Changes in the CRP levels on Days 1, 2, and 7. 3. Duration of oxygen therapy. 4. Number of days in hospital. 5. Number of adverse events. 6. Disease outcome.

Results. If a «cytokine storm» occurs, immune regulatory events will trigger the development of either a protective immune response or an exacerbated inflammatory response. The use of preemptive anti-inflammatory therapy has both a short-term and, most importantly, a long-term effect on the T and B parts of the immune process. These aspects definitely require further research and observation.

Conclusion. The use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters. Primarily, it affects the severity of clinical parameters by improving the general condition already on the first day of observation, and decreasing body temperature to normal values. The changes in the C-reactive protein levels show a significant effect of the IL-6 inhibitor on the systemic inflammatory response.

About the authors

V. N. Antonov

South Ural State Medical University; Regional Clinical Hospital №3

Author for correspondence.
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-3531-3491

д.м.н., проф. каф.

Russian Federation, Chelyabinsk

G. L. Ignatova

South Ural State Medical University; Regional Clinical Hospital №3

Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-0877-6554

д.м.н., проф., зав. каф

Russian Federation, Chelyabinsk

O. V. Pribytkova

South Ural State Medical University; Regional Clinical Hospital №3

Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-0818-9237

к.м.н., зав. отд-нием, гл. внештатный специалист

Russian Federation, Chelyabinsk

S. S. Sleptsova

Ammosov North-Eastern Federal University

Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-0103-4750

д.м.н., доц., зав. каф

Russian Federation, Yakutsk

E. A. Strebkova

Seredavin Samara Regional Clinical Hospital; Samara State Medical University, Samara

Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-0854-2264

к.м.н., доц., зав. отд-нием, внештатный специалист

Russian Federation, Samara

E. A. Khudyakova

. Luke of Crimea Stary Oskol District Hospital, Belgorod Region

Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-4408-1581

зав. отд-нием

Russian Federation, Stary Oskol

A. I. Simakov

Pacific State Medical University; Territorial Clinical Hospital №2

Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-3334-4673

д.м.н., доц., зав. каф. внештатный специалист

Russian Federation, Vladivostok

S. Yu. Rabets

Norilsk Inter-District Hospital №1

Email: ant-vn@yandex.ru
ORCID iD: 0000-0003-4853-4127

зам. глав. врача, клинический фармаколог

Russian Federation, Norilsk

E. P. Tikhonova

Voyno-Yasenetsky Krasnoyarsk State Medical University; Karpovich Krasnoyarsk Inter-District Clinical Emergency Hospital

Email: ant-vn@yandex.ru
ORCID iD: 0000-0001-6466-9609

д.м.н., проф., зав. каф

Russian Federation, Krasnoyarsk

D. Yu. Kurmaeva

Penza Regional Clinical Tertiary Care Centre

Email: ant-vn@yandex.ru
ORCID iD: 0000-0001-7989-7647

к.м.н., зам. глав. врача

Russian Federation, Penza

M. A. Petrushin

Tver Region Regional Clinical Hospital

Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-2780-5138

зав. отд-нием

Russian Federation, Tver

A. S. Mashkov

Voronovskoye Moscow Clinical Center for Infectious Diseases

Email: ant-vn@yandex.ru
ORCID iD: 0000-0003-3465-8372

зав. отд-нием

Russian Federation, Moscow

E. V. Gayazova

Nizhny Novgorod Region City Clinical Hospital №3 (Nizhny Novgorod Geriatric Center)

Email: ant-vn@yandex.ru
ORCID iD: 0000-0001-9621-3550

врач-невролог

Russian Federation, Nizhny Novgorod

I. V. Yasheva

Temporary Infectious Diseases Hospital for Coronavirus Disease based at the Cherkess City Clinical Hospital

Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-2228-5137

зав. отд-нием

Russian Federation, Cherkessk

M. A. Andreev

Republican Tuberculosis Dispensary

Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-4548-2598

зам. глав. врача

Russian Federation, Cheboksary

V. V. Khinovker

Siberian Clinical Research Center

Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-3162-6298

к.м.н., зав. отд-нием

Russian Federation, Krasnoyarsk

A. Yu. Karpunin

Regional Clinical Hospital

Email: ant-vn@yandex.ru
ORCID iD: 0000-0003-0837-8895

к.м.н., глав. врач

Russian Federation, Ryazan

B. V. Berezhanskiy

R-Pharm JSC

Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-2551-9584

к.м.н., ст. мед. советник

Russian Federation, Moscow

References

  1. García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front Immunol. 2020;11:1441. doi: 10.3389/fimmu.2020.01441
  2. Pascarella G, Strumia A, Piliego Ch, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192-206. doi: 10.1111/joim.13091
  3. Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446
  4. Mahmudpour M, Roozbeh J, Keshavarz M, et al. Cytokine. 2020;133:155151. doi: 10.1016/j.cyto.2020.155151
  5. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564-81. doi: 10.1111/all.14364
  6. Shaw S, Bourne T, Meier C, et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014;6(3):774-82. doi: 10.4161/mabs.28612; https://pubmed.ncbi.nlm.nih.gov/24670876
  7. Manjili RH, Zarei M, Habibi M, Manjili MH. COVID-19 as an acute inflammatory disease. J Immunol. 2020;205:12-9. doi: 10.4049/jimmunol.2000413
  8. Felsenstein S, Herbert AJ, McNamara SP, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020;215:108448. doi: 10.1016/j.clim.2020.108448.
  9. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92:424-32. doi: 10.1002/jmv.25685
  10. Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5:917-27. doi: 10.1038/nri1732
  11. Huang AT, Garcia-Carreras B, Hitchings TDM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11(1):4704. doi: 10.1038/s41467-020-18450-4

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies